A strong practice is to pair HSA enrollment materials with a short explanation of pre-tax contribution mechanics so employees understand the difference between payroll-based funding and money they deposit on their own
(2022) Tirzepatide - a dual GIP/GLP-1 receptor agonist - a new antidiabetic drug with potential metabolic activity in the treatment of type 2 diabetes

Contrave highlights of prescribing information, Food and Drug Administration (2024) Wegovy highlights of prescribing information, Food and Drug Administration (2024) Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial, The Lancet (2010) Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension, Diabetes, Obesity and Metabolism (2022) Label: Contrave extended-release naltrexone hydrochloride and bupropion hydrochloride tablet, extended release, DailyMed (2024) Label: Wegovy- semaglutide injection, solution, DailyMed (2024) Update on FDAs ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for Type 2 diabetes and obesity, Food and Drug Administration (2024) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice

Indeed, preventing micelle formation via common bile duct ligation abolishes GIP secretion upon a lard gavage compared to sham controls, independent of meal transit (Shibue et al., 2015)